Phase 3 study of Ophena for treatment of dyspareunia associated with postmenopausal vaginal atrophy - MPR
Links shared publicly online about this topic.
- 1,758total visits
Phase 3 study of Ophena for treatment of dyspareunia associated with postmenopausal vaginal atrophy - MPR
empr.com —
QuatRx Pharmaceuticals announced positive efficacy results from the second of two patient cohorts in its second Phase 3 study for Ophena (ospemifene tablets) for the treatment of dyspareunia (sexual pain) associated with postmenopausal vulvovaginal atrophy (VVA).
View full resource at empr.com
Tags: Pain, Sexual Health, Pharma, Phase 3 Clinical Trial, Sex and Intimacy, Sexual Dysfunction, News
Most Recently Shared on September 10, 2009 at 7:25 pm By:
MPR News: Phase 3 study of Ophena for treatment of dyspareunia associated with postmenopausal vaginal a.. http://bit.ly/ma4hs
Advertisement
